Navigation Links
Shares Of AVI BioPharma Drops On Reports Of Disappointing Early Drug Trail

Shares of AVI BioPharma Inc. has lost a third of their value on Wednesday after the company reported disappointing clinical trial data for its experimental treatment against the hepatitis C virus. //

The shares of AVI were down $2.43, or 33 percent, to $4.83, in the heavy morning trade on the Nasdaq.

The Portland, Oregon based biotechnology company said that the results came from the second stage of a trial involving the antisense drug, called AVI-4065, among patients infected with the liver-damaging virus. Company officials have said that the drug showed favourable safety in all patients treated so far, but patients have experienced only a mean "slight decrease" in the amount of virus in their bloodstreams both during and after treatment.

In a press release the company officials said that during the 14 days of treatment, three of five patients evaluated had an initial decrease in viral load, whereas two of five exhibited little initial change. They were quick to point out that the results were still only preliminary and in only a small number of patients, and that patients remained enrolled in the study. They stated that the formal results of the trial were expected around the end of the year.

Antisense drugs, like AVI-4065, are artificial pieces of genetic material that are meant to prevent genes from expressing disease-causing proteins. Sadly the technology has not yet achieved great success despite high earlier hopes.


'"/>




Page: 1

Related medicine news :

1. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
2. Sun Pharma Allots Shares Upon Fccbs Conversion
3. Zenotech Issues 20 Lakh Shares to Ranbaxy for Rs 20 Cr
4. Female Ratio Drops Alarmingly In Himachal Due To Feticides
5. 1.8 mn Delhi Children to Receive Anti-polio Drops
6. Antibiotic Ear Drops Favored Over Oral Antibiotics for Ear Infections
7. No Smoking During Play Rehearsals: UK’s Health Ministry Drops the Curtain
8. Russia Reports First SARS Case
9. Uganda Reports Failure To Contain Sleeping Sickness
10. Reports of Hantavirus infection in India raise concerns
11. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Sourced from the ... some unique properties including its unmatched natural purity of just 6 ppm TDS (Total ... crisp. , Nothing Water has been available in several ShopRite and FoodTown stores in ...
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... ... care journeys, announced today that it has raised $6.0 million in an initial ... by Clarify Health’s conviction that patients and their caregivers can receive far better ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On Thursday, ... session in red, while the Dow Jones Industrial Average managed ... close of US markets, which prompted Stock-callers this morning to ... Inc. (NASDAQ: NUVA ), Smith & Nephew PLC ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... 2016 Research and Markets has announced ... Cancer - Technologies, Markets and Companies" to their offering. ... , , ... cancer The market value of drug delivery technologies and ... 2015-2025 are given according to organs involved and the types of ...
(Date:12/2/2016)... OLD LYME, Conn. , Dec. 1, 2016 /PRNewswire/ ... consulting, has announced the honor of being selected as ... that include: Simpson Healthcare Executives Website at the PLATINUM ... Directed Conversations Training Module at the GOLD Level, and ... At Simpson Healthcare Executives, we are ...
Breaking Medicine Technology: